A random allocation study to receive one of the trial intervention, to evaluate the safety of breast conserving surgery (surgery to remove cancer while leaving as much normal breast as possible) after giving neo adjuvant therapy in patients with locally advanced breast cancer (large tumors).

Phase 3

• Conditions: Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 2: null- Proven Breast Cancer, who have received neo-adjuvant systemic therapy and are now deemed suitable for BCS

• Registration Number: CTRI/2018/07/014767
• Lead Sponsor: Tata Memorial Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

All women with biopsy proven T3/T4 Any N, Or Any T N2/N3 breast cancer who have received neo-adjuvant systemic therapy and are now deemed suitable for BCS

Women more than 18yrs

Patients who have given consent to participate in the study

Exclusion Criteria

Patients presenting to TMH, post excision Biopsy

Patients who show disease progression despite chemotherapy

Pregnant women/Lactating women.

Inflammatory Breast Cancer

Patients not keen on breast conservation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease free survival at five yearsTimepoint: Disease free survival at five years

Secondary Outcome Measures

Name	Time	Method
Overall survival <br/ ><br>Quality of life <br/ ><br>Post NACT response patterns <br/ ><br>Timepoint: Overall survival will be measured untill death <br/ ><br>QOL will be measured at 5 time points <br/ ><br>and Post NACT response patterns will be taken care after completion of neo adjuvant chemotherapy